MARINE BIOTECH LIMITED - Key Persons
Alex Mühlhölzl, Founder & CTO. Founder & developer of the methodologies that the company has developed in its commercial pilot. Alex has experience in owning and operating businesses and companies. He has had previous experience in aquaculture development for other species. Having worked in Australia on Cherax Destructor (Yabbies) aquaculture and early stage seahorse farming, he also developed technology and methodologies for the breeding of tuna in captivity. Alex brings the skills and mindset of tackling new and unique species in the field of commercial aquaculture to MBL and will manage the day to day operations of the commercial facility.
David Evans, Chairman. David was an initial investor, is a Director of MBL and will continue to oversee the commercialisation stage. David is a Chairman and entrepreneurial investor in a number of companies with a demonstrable track record for providing strategic and commercial advice. Past FD & CEO of Axis Shield and Chairman of DxS, BBI Group, Immunodiagnostics and Sirigen. Also current Chairman of Epistem, EKF Diagnostics, Scancell & Omega Diagnostics.
Scott Johnstone, CEO. Scott has a long and active history with the UK lifescience sector, with his most recent achievement of not being the establishing of the Scottish Lifesciences Association in January 2011. Scott has acted as interim/part-time CEO for a number of companies with interests ranging from veterinary diagnostics to small molecule drug discovery through to regenerative medicine. He was a Technology Entrepreneur to the Scottish Enterprise proof of concept programme and a past member of LiSAB, the Scottish Life Sciences Advisory Board and chaired the Technology Workstream from 2009-2011. From 1998 to April 2004 he was MD and co-founder of YAbA Limited and secured over £2.5m in venture capital to develop and manufacture human and veterinary diagnostic products and prior to this was part of the acquisitions team at Fisons (UK). His addition to MBL brings a wealth of experience in the lifescience sector as well as the commercial experience in helping to guide the company through its transition from pilot to full commercial operations.